Total Disc Replacement Versus Anterior Cervical Decompression and Fusion

  • STATUS
    Recruiting
  • days left to enroll
    14
  • participants needed
    110
  • sponsor
    University Hospital, Bordeaux
Updated on 22 January 2021

Summary

Background : Cervical degenerative disc disease is frequent and the consequence of aging. Degeneration may lead to disc herniation. Surgery is indicated in the presence of root compression with cervicobrachial neuralgia and/or myelopathy.

Purpose: The main objective of the study is the comparison of efficacy between total disc replacement (TDR) and Anterior Cervical Decompression and Fusion (ACDF) as surgical treatment of symptomatic cervical degenerative disc disease in term of "Success" rate, defined as preservation of adjacent segments, 24 months after surgery.

In our knowledge, there are no published data about randomized clinical trials comparing these radiological parameters (worsening of degeneration signs on static cervical spine radiographs and worsening of disc degeneration signs on MRI) at levels adjacent to surgery, between these 2 surgical approaches in patients suffering from cervical degenerative disc disease.

Description

Surgical treatment of cervical degenerative disc disease usually consists in neural decompression followed by intervertebral space reconstruction.

ACDF consists in interbody fusion by replacing disc space with a cage packed with bone substitute, and inserted into the anterior portion of the interspace. Fusion is successful in approximately 95% of patients with good to excellent clinical results in most of them. Unfortunately, up to 25% of these patients will develop degenerative changes at adjacent levels after surgery.

TDR consists in total disc replacement with preserved segmental motion decreasing load on adjacent levels.

Worsening of radiological degeneration signs at adjacent levels seems to be an important long term prognostic factor for reoperation.

In this trial, included patients will be randomly assigned to undergo either TDR or ACDF Six visits are planned during the study: pre inclusion visit within 3 months before surgery, inclusion/randomisation the day before surgery, 3 follow up visits (45 days, 6, and 12 months after surgery) and an end of study visit 24 months after surgery (or at time of withdrawal if relevant).

Details
Condition Cervical Degenerative Disc Disease
Treatment Surgical treatment of cervical degenerative disc disease (CP ESP®), Surgical treatment of cervical degenerative disc disease (Axelle®)
Clinical Study IdentifierNCT02417272
SponsorUniversity Hospital, Bordeaux
Last Modified on22 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 60 yrs?
Gender: Male or Female
Do you have Cervical Degenerative Disc Disease?
Do you have any of these conditions: Do you have Cervical Degenerative Disc Disease??
Aged 18-60 years
suffering from cervical disc degenerative disease (whatever the grade, level and intervertebral disc height) needing one-level surgical treatment due to either invalidating cervicobrachial nevralgia despite 3-month optimal medical treatment or neurological symptoms, with motion of surgical level at least equal to 2 degrees, and non-degenerative adjacent discs
Being affiliated to health insurance
Having signed an informed consent (later than the day of inclusion and before any examination required by research)

Exclusion Criteria

Previous cervical traumatism and/or cervical surgery
Cervical degeneration defined as a Grade 4 according to modified Mehren classification and/or a Grade 5 according to Miyazaki et al classification on T2 magnetic resonance imaging (MRI), at symptomatic level and/or its adjacent levels
Myelopathy
Cervical spine instability
Presence of at least one major contraindication to surgery and/or general anaesthesia (ie, non-controlled coagulopathy, active infection, or serious underlying disease, auto-immune affection)
Presence of at least one contraindication to either TDR or ACDF procedure
Presence of at least one contraindication to either static/dynamic radiographs or Magnetic Resonance Imaging (MRI)
Severe radiological osteoporosis
Bone metabolic disease
Active cancer at time of inclusion into the study
Chronic intake of corticosteroids or any other treatment susceptible to interfere with study conduct and/or assessment (ie, immunosuppressive drugs)
Unlikely to comply with the requirements of the study and/or to complete the study for psychological, social, familial or geographical reasons
No contraception for women of childbearing age
Pregnant or breastfeeding women
Being under guardianship or legal supervision
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note